Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection
The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surfac...
Saved in:
| Published in | Cellular physiology and biochemistry Vol. 51; no. 5; pp. 2377 - 2396 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article Web Resource |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
01.01.2018
Karger Cell Physiol Biochem Press GmbH & Co KG |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses. |
|---|---|
| AbstractList | The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses. The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses.The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses. |
| Author | Shao, Jun-jun Xie, Yin-li Li, Shi-fang Zhao, Fu-rong Zhang, Yong-guang Chang, Hui-yun Gong, Mei-jiao |
| Author_xml | – sequence: 1 givenname: Shi-fang surname: Li fullname: Li, Shi-fang – sequence: 2 givenname: Mei-jiao surname: Gong fullname: Gong, Mei-jiao – sequence: 3 givenname: Fu-rong surname: Zhao fullname: Zhao, Fu-rong – sequence: 4 givenname: Jun-jun surname: Shao fullname: Shao, Jun-jun – sequence: 5 givenname: Yin-li surname: Xie fullname: Xie, Yin-li – sequence: 6 givenname: Yong-guang surname: Zhang fullname: Zhang, Yong-guang email: changhuiyun@caas.cn; zhangyongguang@caas.cn – sequence: 7 givenname: Hui-yun surname: Chang fullname: Chang, Hui-yun email: changhuiyun@caas.cn; zhangyongguang@caas.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30537741$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1v1DAQhi1URD_gwB2hSFzgEOqPOLZ7W7YFIlXiUrhajjNZecnGwXYq9d_j3Sx7qDh5PPO8r8aeuURnox8BobcEfyaEq2uMcaW4VOIFuiAVJaUSQp7lGBNeSiXFObqMcYvzVSj6Cp0zzJkQFblA-uFpgqIpmjFB6CH4Md4Uty4mN9pUfHF-8BtnzVCsbHKPLjmIhRm7Yj2HAGMqVtM05HpyWVj0PhS_XMh0M_Zg98nX6GVvhghvjucV-vn17mH9vbz_8a1Zr-5Lyyueyo61nNUW-qplWFnCFFYYM2YMET0DqmTVA66JqMFIA4KatmtNXfcU10pQzK5Qs_h23mz1FNzOhCftjdOHhA8bbUJydgBNWypbKwwxileM9UopzqAmDHe14FZkL7Z4DQ42kLWt04_0YHaI5yGbWd1mK1pLTSvJJM-qj4tqCv7PDDHpnYsWhsGM4OeoKeGc1JKSfbMfnqFbP4cx_4-mDBNFCJNVpt4fqbndQXd61L_hZeDTAtjgYwzQnxCC9X4x9GkxMnv9jLUuHcaWgnHDfxXvFsVvEzYQTt7H8l8Jzb9B |
| CitedBy_id | crossref_primary_10_1007_s10875_021_01163_8 crossref_primary_10_1016_j_clicom_2022_02_002 crossref_primary_10_1016_j_kint_2022_02_031 crossref_primary_10_1038_s41392_021_00734_w crossref_primary_10_1016_j_dci_2022_104443 crossref_primary_10_3389_fmicb_2022_1006481 crossref_primary_10_3390_nu14071388 crossref_primary_10_21518_ms2023_202 crossref_primary_10_3904_kjim_2023_299 crossref_primary_10_1111_jgh_16926 crossref_primary_10_1016_j_fsi_2024_109875 crossref_primary_10_3390_pathogens11080853 crossref_primary_10_1007_s00011_021_01445_2 crossref_primary_10_1161_JAHA_121_020754 crossref_primary_10_1016_j_cytogfr_2020_07_002 crossref_primary_10_1038_s41435_020_00116_2 crossref_primary_10_3390_biom14070848 crossref_primary_10_1089_vim_2020_0310 crossref_primary_10_1038_s41598_020_58443_3 crossref_primary_10_1016_j_jphs_2024_01_005 crossref_primary_10_1016_j_stem_2021_03_004 crossref_primary_10_3390_cells11111767 crossref_primary_10_3390_v13010047 crossref_primary_10_1016_j_ejphar_2024_176882 crossref_primary_10_1016_j_it_2021_09_003 crossref_primary_10_3389_fimmu_2019_01431 crossref_primary_10_1093_infdis_jiad454 crossref_primary_10_3389_fmed_2021_713153 crossref_primary_10_1371_journal_pgph_0000231 crossref_primary_10_1371_journal_pntd_0010166 crossref_primary_10_3390_biomedicines11092346 crossref_primary_10_1016_j_biopha_2020_111008 crossref_primary_10_1016_j_ymthe_2019_11_011 crossref_primary_10_3390_v11020175 crossref_primary_10_3390_cancers16081600 crossref_primary_10_1111_ijcp_14721 crossref_primary_10_3390_v13020279 crossref_primary_10_1016_j_cyto_2021_155633 crossref_primary_10_3390_v16040564 crossref_primary_10_1016_j_molimm_2022_12_003 crossref_primary_10_1093_rheumatology_kead186 crossref_primary_10_1007_s10067_024_07046_8 crossref_primary_10_1089_jir_2023_0193 crossref_primary_10_1128_JVI_00480_20 crossref_primary_10_1016_j_jphs_2022_04_011 crossref_primary_10_1016_j_biopha_2023_115603 crossref_primary_10_4049_jimmunol_2200420 crossref_primary_10_1016_j_ijbiomac_2021_01_208 crossref_primary_10_3390_v12070733 crossref_primary_10_3389_fpubh_2020_618624 crossref_primary_10_3390_v13071369 crossref_primary_10_1016_j_clim_2021_108842 crossref_primary_10_1089_vim_2020_0085 crossref_primary_10_1007_s00018_022_04290_6 crossref_primary_10_1016_j_bcp_2022_115026 crossref_primary_10_1016_j_jtauto_2021_100093 crossref_primary_10_3390_cells10051134 crossref_primary_10_1186_s12896_020_00605_2 crossref_primary_10_1155_2022_5373787 crossref_primary_10_1002_rmv_2589 crossref_primary_10_1159_000508379 crossref_primary_10_3389_fimmu_2020_606456 crossref_primary_10_1128_spectrum_01144_21 crossref_primary_10_1016_j_actbio_2023_12_039 crossref_primary_10_3389_fimmu_2020_00051 crossref_primary_10_1016_j_mam_2021_101000 crossref_primary_10_3389_fimmu_2021_690477 crossref_primary_10_3390_v16091383 crossref_primary_10_30766_2072_9081_2022_23_1_16_35 crossref_primary_10_1186_s43042_022_00327_4 crossref_primary_10_3390_jpm11080735 crossref_primary_10_3390_v11100961 crossref_primary_10_3390_v14020268 crossref_primary_10_1016_j_heliyon_2022_e09952 crossref_primary_10_1111_cts_12789 crossref_primary_10_3389_fimmu_2022_935800 crossref_primary_10_3390_ijms23041997 crossref_primary_10_1016_j_omtn_2021_12_038 crossref_primary_10_2174_0929867330666230324163414 crossref_primary_10_1016_j_isci_2020_101585 crossref_primary_10_21518_ms2023_492 crossref_primary_10_1016_j_aquaculture_2025_742123 crossref_primary_10_1038_s41598_021_98729_8 crossref_primary_10_1016_j_jid_2019_10_020 crossref_primary_10_3389_fimmu_2022_971674 crossref_primary_10_1038_s41598_019_52282_7 crossref_primary_10_3389_fimmu_2020_606874 crossref_primary_10_3390_ijms222111379 crossref_primary_10_1016_S2213_2600_20_30511_7 crossref_primary_10_1080_14787210_2022_2078307 crossref_primary_10_3389_fonc_2021_769628 crossref_primary_10_3389_fimmu_2022_859749 crossref_primary_10_1002_jmv_27475 crossref_primary_10_1016_j_heliyon_2022_e11744 crossref_primary_10_1111_1346_8138_16727 crossref_primary_10_1016_j_antiviral_2019_04_006 crossref_primary_10_1016_j_crphar_2021_100058 crossref_primary_10_12677_jcpm_2024_34226 crossref_primary_10_3390_ijms231810968 crossref_primary_10_1016_j_jri_2020_103154 crossref_primary_10_3390_ijms21249473 crossref_primary_10_30895_2221_996X_2021_21_1_50_63 crossref_primary_10_1016_j_jid_2021_11_031 crossref_primary_10_3390_v14102180 crossref_primary_10_3390_biology10090856 crossref_primary_10_1016_j_meegid_2021_104836 crossref_primary_10_1016_j_cytogfr_2021_03_006 crossref_primary_10_4103_ijnpnd_ijnpnd_90_20 crossref_primary_10_1038_s41375_022_01578_1 crossref_primary_10_18632_aging_203432 crossref_primary_10_3390_ijms241210115 crossref_primary_10_3390_life12030414 crossref_primary_10_4236_ojneph_2021_113031 crossref_primary_10_1111_vco_12547 crossref_primary_10_1007_s10989_023_10508_3 crossref_primary_10_3390_v12111221 |
| ContentType | Journal Article Web Resource |
| Copyright | 2018 The Author(s). Published by S. Karger AG, Basel 2018 The Author(s). Published by S. Karger AG, Basel. |
| Copyright_xml | – notice: 2018 The Author(s). Published by S. Karger AG, Basel – notice: 2018 The Author(s). Published by S. Karger AG, Basel. |
| DBID | M-- AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 Q33 DOA |
| DOI | 10.1159/000495897 |
| DatabaseName | Karger Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Université de Liège - Open Repository and Bibliography (ORBI) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access url: https://www.karger.com/OpenAccess sourceTypes: Publisher – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1421-9778 |
| EndPage | 2396 |
| ExternalDocumentID | oai_doaj_org_article_2b28bc7a1a95433f99953e6130d675c7 oai_orbi_ulg_ac_be_2268_248385 30537741 10_1159_000495897 495897 |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 0~B 29B 326 36B 3O. 3V. 4.4 53G 5GY 5VS 6J9 7X7 88E 8FI 8FJ 8UI AAFWJ AAYIC ABUWG ACGFO ACGFS ADBBV AENEX AEYAO AFKRA AFPKN AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CS3 CYUIP DIK DU5 E0A E3Z EBS EJD EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HZ~ IAO IHR IPNFZ KQ8 KUZGX M-- M1P ML- N9A O1H O9- OK1 P2P PQQKQ PROAC PSQYO RIG RKO RNS SV3 UJ6 UKHRP 30W AAYXX ABBTS ABWCG ACQXL ADAGL AFSIO AHFRZ AIOBO CAG CITATION COF ITC PHGZM PHGZT RXVBD NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 Q33 PUEGO |
| ID | FETCH-LOGICAL-c545t-d3b536cef4b309c139090033aa17f3e2984fe06176ea8ae72abdba66f20697203 |
| IEDL.DBID | DOA |
| ISSN | 1015-8987 1421-9778 |
| IngestDate | Wed Aug 27 01:14:13 EDT 2025 Fri Jul 25 15:33:51 EDT 2025 Thu Jul 10 23:33:23 EDT 2025 Fri Jul 25 01:54:41 EDT 2025 Wed Feb 19 02:33:55 EST 2025 Tue Jul 01 05:00:08 EDT 2025 Thu Apr 24 23:04:34 EDT 2025 Thu Aug 29 12:04:45 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Immunodeficiency virus Influenza Virus Hepatitis Antiviral Type I IFN classes Viral infection |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. https://creativecommons.org/licenses/by-nc-nd/4.0 2018 The Author(s). Published by S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c545t-d3b536cef4b309c139090033aa17f3e2984fe06176ea8ae72abdba66f20697203 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 scopus-id:2-s2.0-85058602387 |
| OpenAccessLink | https://doaj.org/article/2b28bc7a1a95433f99953e6130d675c7 |
| PMID | 30537741 |
| PQID | 2301911384 |
| PQPubID | 2047990 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2b28bc7a1a95433f99953e6130d675c7 karger_primary_495897 pubmed_primary_30537741 liege_orbi_v2_oai_orbi_ulg_ac_be_2268_248385 crossref_citationtrail_10_1159_000495897 proquest_miscellaneous_2155168210 crossref_primary_10_1159_000495897 proquest_journals_2301911384 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
| PublicationTitle | Cellular physiology and biochemistry |
| PublicationTitleAlternate | Cell Physiol Biochem |
| PublicationYear | 2018 |
| Publisher | S. Karger AG Karger Cell Physiol Biochem Press GmbH & Co KG |
| Publisher_xml | – name: S. Karger AG – name: Karger – name: Cell Physiol Biochem Press GmbH & Co KG |
| References | Curlin ME, Leelawiwat W, Dunne EF, Chonwattana W, Mock PA, Mueanpai F, Thep-Amnuay S, Whitehead SJ, McNicholl JM: Cyclic changes in HIV shedding from the female genital tract during the menstrual cycle. J Infect Dis 2013; 207: 1616-1620.2341765810.1093/infdis/jit063 Soos JM, Subramaniam PS, Hobeika AC, Schiffenbauer J, Johnson HM: The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 1995; 155: 2747-2753.7544384 Ealy AD, Green JA, Alexenko AP, Keisler DH, Roberts RM: Different ovine interferon-tau genes are not expressed identically and their protein products display different activities. Biol Reprod 1998; 58: 566-573.947541510.1095/biolreprod58.2.566 Li SF, Zhao FR, Shao JJ, Xie YL, Chang HY, Zhang YG: Interferon-omega: Current status in clinical applications. Int Immunopharmacol 2017; 52: 253-260.2895769310.1016/j.intimp.2017.08.028 Zhao LJ, He SF, Liu Y, Zhao P, Bian ZQ, Qi ZT: Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha. Cell Physiol Biochem 2016; 40: 77-90.2785537710.1159/000452526 Skorvanova L, Svancarova P, Svetlikova D, Betakova T: Protective efficacy of IFN-omega AND IFN-lambdas against influenza viruses in induced A549 cells. Acta Virol 2015; 59: 413-417.26666190 Guo Y, An D, Liu Y, Bao J, Luo X, Cheng X, Wang Y, Gao M, Wang J: Characterization and signaling pathway analysis of interferon-kappa in bovine. Dev Comp Immunol 2017; 67: 213-220.2769354010.1016/j.dci.2016.09.018 Garcia-Minambres A, Eid SG, Mangan NE, Pade C, Lim SS, Matthews AY, de Weerd NA, Hertzog PJ, Mak J: Interferon epsilon promotes HIV restriction at multiple steps of viral replication. Immunol Cell Biol 2017; 95: 478-483.2804502510.1038/icb.2016.123 Koyama T, Sakamoto N, Tanabe Y, Nakagawa M, Itsui Y, Takeda Y, Kakinuma S, Sekine Y, Maekawa S, Yanai Y, Kurimoto M, Watanabe M: Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006; 34: 41-49.1636468310.1016/j.hepres.2005.10.005 Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, Cointault O, Ribes D, Nogier MB, Alric L, Peron JM, Izopet J: Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010; 139: 1612-1618.2070800610.1053/j.gastro.2010.08.002 Gil S, Leal RO, McGahie D, Sepulveda N, Duarte A, Niza MM, Tavares L: Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation. Res Vet Sci 2014; 96: 79-85.2433227310.1016/j.rvsc.2013.11.007 Leal RO, Gil S, Duarte A, McGahie D, Sepulveda N, Niza MM, Tavares L: Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res Vet Sci 2015; 99: 87-95.2574795610.1016/j.rvsc.2015.02.008 Easlick J, Szubin R, Lantz S, Baumgarth N, Abel K: The early interferon alpha subtype response in infant macaques infected orally with SIV. J Acquir Immune Defic Syndr 2010; 55: 14-28.2061674210.1097/QAI.0b013e3181e696ca Zhang X, Ye Z, Pei Y, Qiu G, Wang Q, Xu Y, Shen B, Zhang J: Neddylation is required for herpes simplex virus type I (HSV-1)-induced early phase interferon-beta production. Cell Mol Immunol 2016; 13: 578-583.2759348210.1038/cmi.2015.35 Wang Y, Li X, Song S, Sun Y, Zhang J, Yu C, Chen W: HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11 HaCaT cells. Virol J 2017; 14: 211.2910052710.1186/s12985-017-0878-2 Osterlund P, Pirhonen J, Ikonen N, Ronkko E, Strengell M, Makela SM, Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I: Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010; 84: 1414-1422.1993992010.1128/JVI.01619-09 Cella M, Facchetti F, Lanzavecchia A, Colonna M: Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1: 305-310.1101710110.1038/79747 Zwarthoff EC, Mooren AT, Trapman J: Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res 1985; 13: 791-804.298781010.1093/nar/13.3.791 Peters van Ton AM, Gevers TJ, Drenth JP: Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 2015; 22: 965-973.2576048110.1111/jvh.12403 Carolan LA, Rockman S, Borg K, Guarnaccia T, Reading P, Mosse J, Kelso A, Barr I, Laurie KL: Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses. J Virol 2015; 90: 2838-2848.2671925910.1128/JVI.02797-15 Tanikawa N, Seno K, Kawahara-Miki R, Kimura K, Matsuyama S, Iwata H, Kuwayama T, Shirasuna K: Interferon Tau Regulates Cytokine Production and Cellular Function in Human Trophoblast Cell Line. J Interferon Cytokine Res 2017; 37: 456-466.2902843110.1089/jir.2017.0057 Donnelly RP, Kotenko SV: Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-564.2071245310.1089/jir.2010.0078 Domenech A, Miro G, Collado VM, Ballesteros N, Sanjose L, Escolar E, Martin S, Gomez-Lucia E: Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet Immunol Immunopathol 2011; 143: 301-306.2171911610.1016/j.vetimm.2011.06.008 Chon TW, Bixler S: Interferon-tau: current applications and potential in antiviral therapy. J Interferon Cytokine Res 2010; 30: 477-485.2062629010.1089/jir.2009.0089 Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, Otten RA, Heneine W, Hendry RM, McNicholl JM, Kersh EN: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57: 261-264.2154684810.1097/QAI.0b013e318220ebd3 Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML: Interferon-alpha Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. Plos Pathog 2015; 11:e1005254.2652941610.1371/journal.ppat.1005254 Johnson JA, Hochkeppel HK, Gangemi JD: IFN-tau exhibits potent suppression of human papillomavirus E6/ E7 oncoprotein expression. J Interferon Cytokine Res 1999; 19: 1107-1116.1054715010.1089/107999099313046 Li J, Li B, Zhang J, Hou L, Yu C, Fu L, Song X, Yu T, Zhang J, Ren J, Xu C, Chen W: Preparation of CHO cell-derived rhIFN-omega-Fc with improved pharmacokinetics. Antiviral Res 2011; 89: 199-203.2127790410.1016/j.antiviral.2011.01.004 Frumence E, Roche M, Krejbich-Trotot P, El-Kalamouni C, Nativel B, Rondeau P, Misse D, Gadea G, Viranaicken W, Despres P: The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-beta production and apoptosis induction. Virology 2016; 493: 217-226.2706056510.1016/j.virol.2016.03.006 Oritani K, Medina KL, Tomiyama Y, Ishikawa J, Okajima Y, Ogawa M, Yokota T, Aoyama K, Takahashi I, Kincade PW, Matsuzawa Y: Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nat Med 2000; 6: 659-666.1083568210.1038/76233 Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A: IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. Embo Mol Med 2016; 8: 1099-1112.2752096910.15252/emmm.201606413 Sekellick MJ, Marcus PI: Interferon induction by viruses. VIII. Vesicular stomatitis virus: [+/-]DI-011 particles induce interferon in the absence of standard virions. Virology 1982; 117: 280-285.617508710.1016/0042-6822(82)90530-X Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, Julkunen I: Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005; 79: 9608-9617.1601492310.1128/JVI.79.15.9608-9617.2005 Jang H, Ngunjiri JM, Lee CW: Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens. Plos One 2016; 11:e156603.2725798910.1371/journal.pone.0156603 De Mari K, Maynard L, Sanquer A, Lebreux B, Eun HM: Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med 2004; 18: 477-482.1532058310.1111/j.1939-1676.2004.tb02570.x Usharani J, Park SY, Cho EJ, Kim C, Ko YJ, Tark D, Kim SM, Park JH, Lee KN, Lee MH, Lee HS: Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus. Antiviral Res 2017; 143: 134-141.2813762310.1016/j.antiviral.2017.01.018 Pontzer CH, Yamamoto JK, Bazer FW, Ott TL, Johnson HM: Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J Immunol 1997; 158: 4351-4357.9126998 Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS, Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010; 53: 146-153.2006834810.1159/000274975 Zhou H, Chen S, Wang M, Cheng A: Interferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulation. Int J Mol Sci 2014; 15: 21045-21068.2540573610.3390/ijms151121045 Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G: Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J 2009; 6: 70.1949334310.1186/1743-422X-6-70 Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von Messling |
| References_xml | – reference: Kawamoto S, Oritani K, Asada H, Takahashi I, Ishikawa J, Yoshida H, Yamada M, Ishida N, Ujiie H, Masaie H, Tomiyama Y, Matsuzawa Y: Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1. J Virol 2003; 77: 9622-9631.1291557410.1128/JVI.77.17.9622-9631.2003 – reference: Veazey RS, Pilch-Cooper HA, Hope TJ, Alter G, Carias AM, Sips M, Wang X, Rodriguez B, Sieg SF, Reich A, Wilkinson P, Cameron MJ, Lederman MM: Prevention of SHIV transmission by topical IFN-beta treatment. Mucosal Immunol 2016; 9: 1528-1536.2683804810.1038/mi.2015.146 – reference: An D, Guo Y, Bao J, Luo X, Liu Y, Ma B, Gao M, Wang J: Molecular characterization and biological activity of bovine interferon-omega3. Res Vet Sci 2017; 115: 125-131.2825441610.1016/j.rvsc.2017.01.028 – reference: Isaacs A, Lindenmann J, Valentine Rc: Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 1957; 147: 268-273.13465721 – reference: Xu C, Song X, Fu L, Dong D, Wu S, Li G, Yi S, Yu T, Yu R, Hou L, Chen W: Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus. Viral Immunol 2011; 24: 369-374.2200413610.1089/vim.2011.0003 – reference: Tanikawa N, Seno K, Kawahara-Miki R, Kimura K, Matsuyama S, Iwata H, Kuwayama T, Shirasuna K: Interferon Tau Regulates Cytokine Production and Cellular Function in Human Trophoblast Cell Line. J Interferon Cytokine Res 2017; 37: 456-466.2902843110.1089/jir.2017.0057 – reference: van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, Filali-Mouhim A, Dupuy FP, Procopio FA, Chomont N, Balderas RS, Said EA, Boulassel MR, Tremblay CL, Routy JP, Sékaly RP, Haddad EK: Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest 2011; 121: 3877-3888.2192646310.1172/JCI59211 – reference: Keshvari M, Alavian SM, Sharafi H, Karimi G, Gholami FM: Interferon alpha-2b therapy in chronic hepatitis delta. Hepat Mon 2014; 14:e15729.2474479010.5812/hepatmon.15729 – reference: Matsumiya T, Xing F, Ebina M, Hayakari R, Imaizumi T, Yoshida H, Kikuchi H, Topham MK, Satoh K, Stafforini DM: Novel role for molecular transporter importin 9 in posttranscriptional regulation of IFN-epsilon expression. J Immunol 2013; 191: 1907-1915.2385168610.4049/jimmunol.1201925 – reference: Takahashi T, Sakumoto R, Hayashi KG, Hosoe M, Shirai J, Hashizume K: Generation of recombinant bovine interferon tau in the human embryonic kidney cell line and its biological activity. Anim Sci J 2017; 88: 1498-1505.2855841910.1111/asj.12820 – reference: Leal RO, Gil S: The Use of Recombinant Feline Interferon Omega Therapy as an Immune-Modulator in Cats Naturally Infected with Feline Immunodeficiency Virus: New Perspectives. Vet Sci 2016; 3.2905674010.3390/vetsci3040032 – reference: Whaley AE, Meka CS, Harbison LA, Hunt JS, Imakawa K: Identification and cellular localization of unique interferon mRNA from human placenta. J Biol Chem 1994; 269: 10864-10868.7511610 – reference: Rohloff CM, Alessi TR, Yang B, Dahms J, Carr JP, Lautenbach SD: DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008; 2: 461-467.1988521110.1177/193229680800200316 – reference: Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C: Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol 2008; 180: 7158-7166.1849071410.4049/jimmunol.180.11.7158 – reference: Utay NS, Douek DC: Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathog Immun 2016; 1: 107-116.2750028110.20411/pai.v1i1.125 – reference: Demers A, Kang G, Ma F, Lu W, Yuan Z, Li Y, Lewis M, Kraiselburd EN, Montaner L, Li Q: The mucosal expression pattern of interferon-epsilon in rhesus macaques. J Leukoc Biol 2014; 96: 1101-1107.2513929010.1189/jlb.3A0214-088RRR – reference: Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; AIDS Clinical Trials Group A5192 Team: Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201: 1686-1696.2042051010.1086/652420 – reference: Pontzer CH, Yamamoto JK, Bazer FW, Ott TL, Johnson HM: Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J Immunol 1997; 158: 4351-4357.9126998 – reference: Walter MR, Bordens R, Nagabhushan TL, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM: Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm 1998; 13: 143-154.1085035010.1089/cbr.1998.13.143 – reference: Ealy AD, Larson SF, Liu L, Alexenko AP, Winkelman GL, Kubisch HM, Bixby JA, Roberts RM: Polymorphic forms of expressed bovine interferon-tau genes: relative transcript abundance during early placental development, promoter sequences of genes and biological activity of protein products. Endocrinology 2001; 142: 2906-2915.11416010 10.1210/endo.142.7.8249 – reference: Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T, Yoshikai Y. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res 2013; 99: 230-237.2372194310.1016/j.antiviral.2013.05.007 – reference: Kohara J, Nishikura Y, Konnai S, Tajima M, Onuma M: Effects of interferon-tau on cattle persistently infected with bovine viral diarrhea virus. JPN J Vet Res 2012; 60: 63-70.23094581 – reference: Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uze G, Pellegrini S, Coccia EM: Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol 2006; 79: 1286-1294.1662493210.1189/jlb.1205742 – reference: Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A: IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. Embo Mol Med 2016; 8: 1099-1112.2752096910.15252/emmm.201606413 – reference: Peters van Ton AM, Gevers TJ, Drenth JP: Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 2015; 22: 965-973.2576048110.1111/jvh.12403 – reference: Ambrus JS, Dembinski W, Chadha K, Ambrus JJ, Chadha KC: Resistance to interferons. Discov Med 2004; 4: 310-314.20704966 – reference: Rogez-Kreuz C, Maneglier B, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, Clayette P: Involvement of IL-6 in the anti-human immunodeficiency virus activity of IFN-tau in human macrophages. Int Immunol 2005; 17: 1047-1057.1597603310.1093/intimm/dxh285 – reference: Todt D, François C, Anggakusuma, Behrendt P, Engelmann M, Knegendorf L, Vieyres G, Wedemeyer H, Hartmann R, Pietschmann T, Duverlie G, Steinmann E: Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother 2016; 60: 2132-2139.2678770110.1128/AAC.02427-15 – reference: Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, Julkunen I: Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005; 79: 9608-9617.1601492310.1128/JVI.79.15.9608-9617.2005 – reference: Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA, Schjenken JE, Parker B, Gargett CE, Nguyen HP, Carr DJ, Hansbro PM, Hertzog PJ: Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013; 339: 1088-1092.2344959110.1126/science.1233321 – reference: Roberts RM, Liu L, Alexenko A: New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. Prog Nucleic Acid Res Mol Biol 1997; 56: 287-325.9187057 – reference: van de Garde MDB, Pas SD, van Oord GW, Gama L, Choi Y, de Man RA, Boonstra A, Vanwolleghem T: Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Sci Rep 2017; 7: 8267.2881149210.1038/s41598-017-07434-y – reference: Guo Y, An D, Liu Y, Bao J, Luo X, Cheng X, Wang Y, Gao M, Wang J: Characterization and signaling pathway analysis of interferon-kappa in bovine. Dev Comp Immunol 2017; 67: 213-220.2769354010.1016/j.dci.2016.09.018 – reference: Diaz MO, Bohlander S, Allen G: Nomenclature of the human interferon genes. J Interferon Res 1994; 14: 221-222.752981010.1089/jir.1994.14.221 – reference: Gibbert K, Schlaak JF, Yang D, Dittmer U: IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol 2013; 168: 1048-1058.2307233810.1111/bph.12010 – reference: Leal RO, Gil S, Sepulveda N, McGahie D, Duarte A, Niza MM, Tavares L: Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-omega therapy. J Small Anim Pract 2014; 55: 39-45.2427964010.1111/jsap.12160 – reference: Maney SK, Xu HC, Huang J, Pandyra AA, Ehlting C, Aguilar-Valenzuela R, Pozdeev VI, McIlwain DR, Zimmermann A, Bode JG, Hengel H, Kirschning CJ, Kim IR, Hiscott J, Brenner D, Häussinger D, Ohashi PS, Mak TW, Lang KS, Lang PA: RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production. Cell Physiol Biochem 2016; 39: 1271-1280.2760646610.1159/000447832 – reference: Yang L, Xu L, Li Y, Li J, Bi Y, Liu W: Molecular and functional characterization of canine interferon-epsilon. J Interferon Cytokine Res 2013; 33: 760-768.2396457010.1089/jir.2013.0037 – reference: Pinto LA, Blazevic V, Patterson BK, Mac TC, Dolan MJ, Shearer GM: Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation. J Virol 2000; 74: 4505-4511.1077558610.1128/JVI.74.10.4505-4511.2000 – reference: Johnson JA, Hochkeppel HK, Gangemi JD: IFN-tau exhibits potent suppression of human papillomavirus E6/ E7 oncoprotein expression. J Interferon Cytokine Res 1999; 19: 1107-1116.1054715010.1089/107999099313046 – reference: Maneglier B, Rogez-Kreuz C, Dereuddre-Bosquet N, Martal J, Devillier P, Dormont D, Clayette P: Anti-HIV effects of IFN-tau in human macrophages: role of cellular antiviral factors and interleukin-6. Pathol Biol 2008; 56: 492-503.1884235810.1016/j.patbio.2008.06.002 – reference: Li SF, Zhao FR, Shao JJ, Xie YL, Chang HY, Zhang YG: Interferon-omega: Current status in clinical applications. Int Immunopharmacol 2017; 52: 253-260.2895769310.1016/j.intimp.2017.08.028 – reference: Reis LF, Ho LT, Vilcek J: Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts. J Biol Chem 1989; 264: 16351-16354.2550437 – reference: Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P: Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res 2007; 73: 118-125.1698755510.1016/j.antiviral.2006.08.005 – reference: Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E: Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-832.2056435210.1002/hep.23743 – reference: Abdulhaqq SA, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton KE, Joseph J, Garced S, Tomaras GD, Linn KA, Foulkes AS, Azzoni L, VerMilyea M, Coutifaris C, Kossenkov AV, Showe L, Kraiselburd EN, Li Q, Montaner LJ: HIV-1-negative female sex workers sustain high cervical IFNvarepsilon, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol 2016; 9: 1027-1038.2655570810.1038/mi.2015.116 – reference: Goyal A, Murray JM: Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China. Clin Drug Investig 2016; 36: 637-648.2716662810.1007/s40261-016-0409-8 – reference: Zhao X, Cheng G, Jiao Y, Yan W, Liu M, Zheng Z: Cloning and characterization of porcine interferon-delta-related genes identified by genomic database screening. J Interferon Cytokine Res 2012; 32: 378-385.2279950410.1089/jir.2011.0095 – reference: Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ: Characterization of the type I interferon locus and identification of novel genes. Genomics 2004; 84: 331-345.1523399710.1016/j.ygeno.2004.03.003 – reference: Yang LM, Xue QH, Sun L, Zhu YP, Liu WJ: Cloning and characterization of a novel feline IFN-omega. J Interferon Cytokine Res 2007; 27: 119-127.1731613910.1089/jir.2006.0094 – reference: Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina JM, Livrozet JM, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C: Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. Aids 2001; 15: 1435-1437.1150496610.1097/00002030-200107270-00014 – reference: Li J, Li B, Zhang J, Hou L, Yu C, Fu L, Song X, Yu T, Zhang J, Ren J, Xu C, Chen W: Preparation of CHO cell-derived rhIFN-omega-Fc with improved pharmacokinetics. Antiviral Res 2011; 89: 199-203.2127790410.1016/j.antiviral.2011.01.004 – reference: Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T, Stubenrauch F: High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 2011; 85: 11372-11380.2184943110.1128/JVI.05279-11 – reference: Matzinger SR, Carroll TD, Fritts L, McChesney MB, Miller CJ: Exogenous IFN-alpha administration reduces influenza A virus replication in the lower respiratory tract of rhesus macaques. Plos One 2011; 6:e29255.2222020910.1371/journal.pone.0029255 – reference: Gil S, Leal RO, McGahie D, Sepulveda N, Duarte A, Niza MM, Tavares L: Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation. Res Vet Sci 2014; 96: 79-85.2433227310.1016/j.rvsc.2013.11.007 – reference: Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.1248321010.1038/ni875 – reference: Zhao X, Cheng G, Yan W, Liu M, He Y, Zheng Z: Characterization and virus-induced expression profiles of the porcine interferon-omega multigene family. J Interferon Cytokine Res 2009; 29: 687-693.1979299810.1089/jir.2008.0060 – reference: Matsumiya T, Prescott SM, Stafforini DM: IFN-epsilon mediates TNF-alpha-induced STAT1 phosphorylation and induction of retinoic acid-inducible gene-I in human cervical cancer cells. J Immunol 2007; 179: 4542-4549.1787835110.4049/jimmunol.179.7.4542 – reference: Adolf GR: Human interferon omega–a review. Mult Scler 1995;S44-S47.9345398 – reference: Oritani K, Medina KL, Tomiyama Y, Ishikawa J, Okajima Y, Ogawa M, Yokota T, Aoyama K, Takahashi I, Kincade PW, Matsuzawa Y: Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nat Med 2000; 6: 659-666.1083568210.1038/76233 – reference: Matikainen S, Pirhonen J, Miettinen M, Lehtonen A, Govenius-Vintola C, Sareneva T, Julkunen I: Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages. Virology 2000; 276: 138-147.1102200210.1006/viro.2000.0542 – reference: Buitendijk M, Eszterhas SK, Howell AL: Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses 2013; 29: 907-918.2331675510.1089/aid.2012.0313 – reference: Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS, Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010; 53: 146-153.2006834810.1159/000274975 – reference: He X, Korytar T, Schatz J, Freuling CM, Muller T, Kollner B: Anti-lyssaviral activity of interferons kappa and omega from the serotine bat, Eptesicus serotinus. J Virol 2014; 88: 5444-5454.2457441310.1128/JVI.03403-13 – reference: Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D’Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V: Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-1120.2464594310.1056/NEJMoa1215246 – reference: Konde MK, Baker DP, Traore FA, Sow MS, Camara A, Barry AA, Mara D, Barry A, Cone M, Kaba I, Richard AA, Beavogui AH, Gunther S, Pintilie M, Fish EN: Interferon beta-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. Plos One 2017; 12:e169255.2822576710.1371/journal.pone.0169255 – reference: Zhao LJ, He SF, Liu Y, Zhao P, Bian ZQ, Qi ZT: Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha. Cell Physiol Biochem 2016; 40: 77-90.2785537710.1159/000452526 – reference: Koyama T, Sakamoto N, Tanabe Y, Nakagawa M, Itsui Y, Takeda Y, Kakinuma S, Sekine Y, Maekawa S, Yanai Y, Kurimoto M, Watanabe M: Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006; 34: 41-49.1636468310.1016/j.hepres.2005.10.005 – reference: Arilahti V, Makela SM, Tynell J, Julkunen I, Osterlund P: Novel avian influenza A (H7N9) virus induces impaired interferon responses in human dendritic cells. Plos One 2014; 9:e96350.2480473210.1371/journal.pone.0096350 – reference: Soos JM, Subramaniam PS, Hobeika AC, Schiffenbauer J, Johnson HM: The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 1995; 155: 2747-2753.7544384 – reference: Roberts RM: Interferon-tau, a Type 1 interferon involved in maternal recognition of pregnancy. Cytokine Growth Factor Rev 2007; 18: 403-408.1766264210.1016/j.cytogfr.2007.06.010 – reference: Ishida N, Oritani K, Shiraga M, Yoshida H, Kawamoto S, Ujiie H, Masaie H, Ichii M, Tomiyama Y, Kanakura Y: Differential effects of a novel IFN-zeta/limitin and IFN-alpha on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes. Exp Hematol 2005; 33: 495-503.1578134110.1016/j.exphem.2005.01.002 – reference: Lefevre F, Guillomot M, D’Andrea S, Battegay S, La Bonnardiere C: Interferon-delta: the first member of a novel type I interferon family. Biochimie 1998; 80: 779-788.986549910.1016/S0300-9084(99)80030-3 – reference: Schoggins JW, Rice CM: Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011; 1: 519-525.2232891210.1016/j.coviro.2011.10.008 – reference: Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M: Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/ hepatitis C virus-coinfected patients. J Infect Dis 2014; 209: 1315-1320.2427774310.1093/infdis/jit628 – reference: Sekellick MJ, Marcus PI: Interferon induction by viruses. VIII. Vesicular stomatitis virus: [+/-]DI-011 particles induce interferon in the absence of standard virions. Virology 1982; 117: 280-285.617508710.1016/0042-6822(82)90530-X – reference: Oritani K, Hirota S, Nakagawa T, Takahashi I, Kawamoto S, Yamada M, Ishida N, Kadoya T, Tomiyama Y, Kincade PW, Matsuzawa Y: T lymphocytes constitutively produce an interferonlike cytokine limitin characterized as a heat- and acid-stable and heparin-binding glycoprotein. Blood 2003; 101: 178-185.1239365310.1182/blood-2002-01-0045 – reference: Tennakoon DK, Smith R, Stewart MD, Spencer TE, Nayak M, Welsh CJ: Ovine IFN-tau modulates the expression of MHC antigens on murine cerebrovascular endothelial cells and inhibits replication of Theiler’s virus. J Interferon Cytokine Res 2001; 21: 785-792.1171098910.1089/107999001753238015 – reference: De Mari K, Maynard L, Sanquer A, Lebreux B, Eun HM: Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med 2004; 18: 477-482.1532058310.1111/j.1939-1676.2004.tb02570.x – reference: Ealy AD, Green JA, Alexenko AP, Keisler DH, Roberts RM: Different ovine interferon-tau genes are not expressed identically and their protein products display different activities. Biol Reprod 1998; 58: 566-573.947541510.1095/biolreprod58.2.566 – reference: Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, Otten RA, Heneine W, Hendry RM, McNicholl JM, Kersh EN: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57: 261-264.2154684810.1097/QAI.0b013e318220ebd3 – reference: Tuo W, MacMillan H, Gunter N, Bazer FW, Brown WC: Upregulation of interleukin-4 and IFN-gamma expression by IFN-tau, a member of the type I IFN family. J Interferon Cytokine Res 1999; 19: 179-187.1009040310.1089/107999099314324 – reference: Zhou H, Chen S, Wang M, Cheng A: Interferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulation. Int J Mol Sci 2014; 15: 21045-21068.2540573610.3390/ijms151121045 – reference: Khuroo MS, Khuroo MS: Hepatitis E: an emerging global disease - from discovery towards control and cure. J Viral Hepat 2016; 23: 68-79.2634493210.1111/jvh.12445 – reference: Ceron JJ, Eckersall PD, Martynez-Subiela S: Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 2005; 34: 85-99.1590265810.1111/j.1939-165X.2005.tb00019.x – reference: Chon TW, Bixler S: Interferon-tau: current applications and potential in antiviral therapy. J Interferon Cytokine Res 2010; 30: 477-485.2062629010.1089/jir.2009.0089 – reference: Detournay O, Morrison DA, Wagner B, Zarnegar B, Wattrang E: Genomic analysis and mRNA expression of equine type I interferon genes. J Interferon Cytokine Res 2013; 33: 746-759.2377295310.1089/jir.2012.0130 – reference: Spivak AM, Planelles V: Novel Latency Reversal Agents for HIV-1 Cure. Annu Rev Med. 2018; 69: 421-436.2909967710.1146/annurev-med-052716-031710 – reference: Bam RA, Hansen D, Irrinki A, Mulato A, Jones GS, Hesselgesser J, Frey CR, Cihlar T, Yant SR: TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother 2016; 61.2779921810.1128/AAC.01369-16 – reference: Cochet M, Vaiman D, Lefevre F: Novel interferon delta genes in mammals: cloning of one gene from the sheep, two genes expressed by the horse conceptus and discovery of related sequences in several taxa by genomic database screening. Gene 2009; 433: 88-99.1911004110.1016/j.gene.2008.11.026 – reference: Donnelly RP, Kotenko SV: Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-564.2071245310.1089/jir.2010.0078 – reference: Pestka S, Krause CD, Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.1554638310.1111/j.0105-2896.2004.00204.x – reference: Buontempo PJ, Jubin RG, Buontempo CA, Wagner NE, Reyes GR, Baroudy BM: Antiviral activity of transiently expressed IFN-kappa is cell-associated. J Interferon Cytokine Res 2006; 26: 40-52.1642614710.1089/jir.2006.26.40 – reference: Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G: Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J 2009; 6: 70.1949334310.1186/1743-422X-6-70 – reference: Kawamoto S, Oritani K, Asakura E, Ishikawa J, Koyama M, Miyano K, Iwamoto M, Yasuda S, Nakakubo H, Hirayama F, Ishida N, Ujiie H, Masaie H, Tomiyama Y: A new interferon, limitin, displays equivalent immunomodulatory and antitumor activities without myelosuppressive properties as compared with interferon-alpha. Exp Hematol 2004; 32: 797-805.1534528010.1016/j.exphem.2004.06.008 – reference: De Maeyer E and De Maeyer-Guignard J: Type I interferons. Int Rev Immunol 1998; 17: 53-73.991494310.3109/08830189809084487 – reference: Usharani J, Park SY, Cho EJ, Kim C, Ko YJ, Tark D, Kim SM, Park JH, Lee KN, Lee MH, Lee HS: Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus. Antiviral Res 2017; 143: 134-141.2813762310.1016/j.antiviral.2017.01.018 – reference: Frumence E, Roche M, Krejbich-Trotot P, El-Kalamouni C, Nativel B, Rondeau P, Misse D, Gadea G, Viranaicken W, Despres P: The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-beta production and apoptosis induction. Virology 2016; 493: 217-226.2706056510.1016/j.virol.2016.03.006 – reference: Tasker C, Subbian S, Gao P, Couret J, Levine C, Ghanny S, Soteropoulos P, Zhao X, Landau N, Lu W, Chang TL: IFN-epsilon protects primary macrophages against HIV infection. JCI Insight 2016; 1:e88255.2794258410.1172/jci.insight.88255 – reference: Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML: Interferon-alpha Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. Plos Pathog 2015; 11:e1005254.2652941610.1371/journal.ppat.1005254 – reference: Smith DB, Simmonds P; International Committee on Taxonomy of Viruses Hepeviridae Study Group, Jameel S, Emerson SU, Harrison TJ, Meng XJ, Okamoto H, Van der Poel WH, Purdy MA: Consensus proposals for classification of the family Hepeviridae. J Gen Virol. 2014; 95: 2223-32.2498917210.1099/vir.0.068429-0 – reference: Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG: Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 2010; 16: 474-477.2037345810.1002/lt.22014 – reference: Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T, Yoshikai Y: Type I interferon plays opposing roles in cytotoxicity and interferon-gamma production by natural killer and CD8 T cells after influenza A virus infection in mice. J Innate Immun 2014; 6: 456-466.2443516610.1159/000356824 – reference: Osterlund P, Strengell M, Sarin LP, Poranen MM, Fagerlund R, Melen K, Julkunen I: Incoming influenza A virus evades early host recognition, while influenza B virus induces interferon expression directly upon entry. J Virol 2012; 86: 11183-11193.2285550110.1128/JVI.01050-12 – reference: Strayer DR, Carter WA, Stouch BC, Stittelaar KJ, Thoolen RJ, Osterhaus AD, Mitchell WM: Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-alpha administered to the buccal mucosa. Antiviral Res 2014; 110: 175-180.2511190510.1016/j.antiviral.2014.07.010 – reference: Owczarek CM, Hwang SY, Holland KA, Gulluyan LM, Tavaria M, Weaver B, Reich NC, Kola I, Hertzog PJ: Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem 1997; 272: 23865-23870.929533510.1074/jbc.272.38.23865 – reference: Habiger C, Jager G, Walter M, Iftner T, Stubenrauch F: Interferon Kappa Inhibits Human Papillomavirus 31 Transcription by Inducing Sp100 Proteins. J Virol 2015; 90: 694-704.2649116910.1128/JVI.02137-15 – reference: Villaverde MS, Gil-Cardeza ML, Glikin GC, Finocchiaro LM: Interferon-beta lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-beta gene transfer to human tumor cells. Cancer Gene Ther 2012; 19: 420-430.2255550810.1038/cgt.2012.19 – reference: Duc-Goiran P, Robert-Galliot B, Lopez J, Chany C: Unusual apparently constitutive interferons and antagonists in human placental blood. Proc Natl Acad Sci U S A 1985; 82: 5010-5014.241091110.1073/pnas.82.15.5010 – reference: Lin FC, Young HA: Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev 2014: 25: 369-376.2515642110.1016/j.cytogfr.2014.07.015 – reference: Stifter SA, Matthews AY, Mangan NE: Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ. J Biol Chem 2018; 293: 3168-3179.2918760310.1074/jbc.M117.800755 – reference: Zhang X, Ye Z, Pei Y, Qiu G, Wang Q, Xu Y, Shen B, Zhang J: Neddylation is required for herpes simplex virus type I (HSV-1)-induced early phase interferon-beta production. Cell Mol Immunol 2016; 13: 578-583.2759348210.1038/cmi.2015.35 – reference: Guo Y, Gao M, Bao J, Luo X, Liu Y, An D, Zhang H, Ma B, Wang J: Molecular cloning and characterization of a novel bovine IFN-epsilon. Gene 2015; 558: 25-30.2552309510.1016/j.gene.2014.12.031 – reference: Curlin ME, Leelawiwat W, Dunne EF, Chonwattana W, Mock PA, Mueanpai F, Thep-Amnuay S, Whitehead SJ, McNicholl JM: Cyclic changes in HIV shedding from the female genital tract during the menstrual cycle. J Infect Dis 2013; 207: 1616-1620.2341765810.1093/infdis/jit063 – reference: Skorvanova L, Svancarova P, Svetlikova D, Betakova T: Protective efficacy of IFN-omega AND IFN-lambdas against influenza viruses in induced A549 cells. Acta Virol 2015; 59: 413-417.26666190 – reference: Domenech A, Miro G, Collado VM, Ballesteros N, Sanjose L, Escolar E, Martin S, Gomez-Lucia E: Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet Immunol Immunopathol 2011; 143: 301-306.2171911610.1016/j.vetimm.2011.06.008 – reference: Cella M, Facchetti F, Lanzavecchia A, Colonna M: Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1: 305-310.1101710110.1038/79747 – reference: Sang Y, Rowland RR, Hesse RA, Blecha F: Differential expression and activity of the porcine type I interferon family. Physiol Genomics 2010; 42: 248-258.2040684910.1152/physiolgenomics.00198.2009 – reference: Todt D, Francois C, Anggakusuma, Behrendt P, Engelmann M, Knegendorf L, Vieyres G, Wedemeyer H, Hartmann R, Pietschmann T, Duverlie G, Steinmann E: Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother 2016; 60: 2132-2139.2678770110.1128/AAC.02427-15 – reference: Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von Messling V: Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009; 83: 3843-3851.1919379210.1128/JVI.02453-08 – reference: Zan J, Zhang H, Gu AP, Zhong KL, Lu MY, Bai XX, Zhang JY, Cai J: Yin Yang 1 Dynamically Regulates Antiviral Innate Immune Responses During Viral Infection. Cell Physiol Biochem 2017; 44: 607-617.2916170110.1159/000485116 – reference: Zwarthoff EC, Mooren AT, Trapman J: Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res 1985; 13: 791-804.298781010.1093/nar/13.3.791 – reference: DeCarlo CA, Severini A, Edler L, Escott NG, Lambert PF, Ulanova M, Zehbe I: IFN-kappa, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Invest 2010; 90: 1482-1491.2047971610.1038/labinvest.2010.95 – reference: Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E: Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 2000; 74: 4957-4966.1079956910.1128/JVI.74.11.4957-4966.2000 – reference: Rogez-Kreuz C, Maneglier B, Dereuddre-Bosquet N, Dormont D, Clayette P: Lack of IFN-gamma production in response to antigenic stimulation in human IFN-tau-treated lymphocytes. J Interferon Cytokine Res 2005; 25: 444-452.1610872710.1089/jir.2005.25.444 – reference: Lachova V, Skorvanova L, Svetlikova D, Turianova L, Kostrabova A, Betakova T: Comparison of transcriptional profiles of interferons, CXCL10 and RIG-1 in influenza infected A549 cells stimulated with exogenous interferons. Acta Virol 2017; 61: 183-190.2852392410.4149/av_2017_02_07 – reference: Hagelstein J, Kist A, Stremmel W, Galle PR: Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells. Arzneimittelforschung 1998; 48: 343-347.9553691 – reference: Nyman TA, Kalkkinen N, Tolo H, Helin J: Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon-alpha2b and interferon-alpha14c produced by Sendai-virus-induced human peripheral blood leukocytes. Eur J Biochem 1998; 253: 485-493.965410110.1046/j.1432-1327.1998.2530485.x – reference: Nakajima A, Sokawa Y: Induction of blood 2’,5’-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau. J Interferon Cytokine Res 2002; 22: 397-402.1203404810.1089/107999002753675839 – reference: Leaman DW, Roberts RM: Genes for the trophoblast interferons in sheep, goat, and musk ox and distribution of related genes among mammals. J Interferon Res 1992; 12: 1-11.137410710.1089/jir.1992.12.1 – reference: Shepherd FA, Beaulieu R, Gelmon K, Thuot CA, Sawka C, Read S, Singer J: Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16: 1736-1742.958688610.1200/JCO.1998.16.5.1736 – reference: Cui H, Liu Y, Huang Y: Roles of TRIM32 in Corneal Epithelial Cells After Infection with Herpes Simplex Virus. Cell Physiol Biochem 2017; 43: 801-811.2895425910.1159/000481563 – reference: Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE: Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res 2005; 65: 23-34.1565296810.1016/j.antiviral.2004.09.002 – reference: Martin V, Pascual E, Avia M, Rangel G, de Molina A, Alejo A, Sevilla N: A Recombinant Adenovirus Expressing Ovine Interferon Tau Prevents Influenza Virus-Induced Lethality in Mice. J Virol 2016; 90: 3783-3788.2673905810.1128/JVI.03258-15 – reference: Osterlund P, Pirhonen J, Ikonen N, Ronkko E, Strengell M, Makela SM, Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I: Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010; 84: 1414-1422.1993992010.1128/JVI.01619-09 – reference: Kohara J, Yokomizo Y: In vitro and in vivo effects of recombinant bovine interferon-tau on bovine leukemia virus. J Vet Med Sci 2007; 69: 15-19.1728339410.1292/jvms.69.15 – reference: Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uze G: Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.1499160910.1002/eji.200324610 – reference: Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y: Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 2001; 12: 337-348.1154410310.1016/S1359-6101(01)00009-0 – reference: Pontzer CH, Ott TL, Bazer FW, Johnson HM: Structure/function studies with interferon tau: evidence for multiple active sites. J Interferon Res 1994; 14: 133-141.793076010.1089/jir.1994.14.133 – reference: Wang Y, Li X, Song S, Sun Y, Zhang J, Yu C, Chen W: HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11 HaCaT cells. Virol J 2017; 14: 211.2910052710.1186/s12985-017-0878-2 – reference: Garcia-Minambres A, Eid SG, Mangan NE, Pade C, Lim SS, Matthews AY, de Weerd NA, Hertzog PJ, Mak J: Interferon epsilon promotes HIV restriction at multiple steps of viral replication. Immunol Cell Biol 2017; 95: 478-483.2804502510.1038/icb.2016.123 – reference: Rivero-Juarez A, Gonzalez R, Frias M, Manzanares-Martin B, Rodriguez-Cano D, Perez-Camacho I, Gordon A, Cuenca F, Camacho A, Pineda JA, Pena J, Rivero A: KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. Pharmacogenomics J 2017; 17: 360-365.2697522910.1038/tpj.2016.19 – reference: Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P: Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol 2006; 99: 62-70.1686717310.1111/j.1742-7843.2006.pto_365.x – reference: Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, Jafri W: Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002; 36: 474-478.1214305810.1053/jhep.2002.34856 – reference: Carolan LA, Rockman S, Borg K, Guarnaccia T, Reading P, Mosse J, Kelso A, Barr I, Laurie KL: Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses. J Virol 2015; 90: 2838-2848.2671925910.1128/JVI.02797-15 – reference: Santhakumar D, Iqbal M, Nair V, Munir M: Chicken IFN Kappa: A Novel Cytokine with Antiviral Activities. Sci Rep 2017; 7: 2719.2857842310.1038/s41598-017-02951-2 – reference: Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G: Binding and activity of all human alpha interferon subtypes. Cytokine 2011; 56: 282-289.2185616710.1016/j.cyto.2011.07.019 – reference: Thomas JM, Pos Z, Reinboth J, Wang RY, Wang E, Frank GM, Lusso P, Trinchieri G, Alter HJ, Marincola FM, Thomas E: Differential responses of plasmacytoid dendritic cells to influenza virus and distinct viral pathogens. J Virol 2014; 88: 10758-10766.2500891810.1128/JVI.01501-14 – reference: Rogez C, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, Clayette P: Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J Virol 2003; 77: 12914-12920.1461021410.1128/JVI.77.23.12914-12920.2003 – reference: Ballin AC, Schulz B, Helps C, Sauter-Louis C, Mueller RS, Hartmann K: Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease. Vet J 2014; 202: 466-470.2545726110.1016/j.tvjl.2014.09.030 – reference: Jang H, Ngunjiri JM, Lee CW: Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens. Plos One 2016; 11:e156603.2725798910.1371/journal.pone.0156603 – reference: Peng FW, Duan ZJ, Zheng LS, Xie ZP, Gao HC, Zhang H, Li WP, Hou YD: Purification of recombinant human interferon-epsilon and oligonucleotide microarray analysis of interferon-epsilon-regulated genes. Protein Expr Purif 2007; 53: 356-362.1728713110.1016/j.pep.2006.12.013 – reference: Leal RO, Gil S, Duarte A, McGahie D, Sepulveda N, Niza MM, Tavares L: Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res Vet Sci 2015; 99: 87-95.2574795610.1016/j.rvsc.2015.02.008 – reference: Easlick J, Szubin R, Lantz S, Baumgarth N, Abel K: The early interferon alpha subtype response in infant macaques infected orally with SIV. J Acquir Immune Defic Syndr 2010; 55: 14-28.2061674210.1097/QAI.0b013e3181e696ca – reference: Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, Cointault O, Ribes D, Nogier MB, Alric L, Peron JM, Izopet J: Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010; 139: 1612-1618.2070800610.1053/j.gastro.2010.08.002 – reference: Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S: Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 2009; 29: 4778-4787.1956441110.1128/MCB.01808-08 – reference: Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke Braun P, Mihm S, Klucher KM: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.1700690610.1002/hep.21312 – reference: Villaverde MS, Targovnik AM, Miranda MV, Finocchiaro LM, Glikin GC: Cytotoxic effects induced by interferon-omega gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells. Cytokine 2016; 84: 47-55.2723635410.1016/j.cyto.2016.05.018 – reference: LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA: Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 2001; 276: 39765-39771.1151454210.1074/jbc.M102502200 – reference: Ramos EL: Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res 2010; 30: 591-595.2064587310.1089/jir.2010.0066 |
| RestrictionsOnAccess | open access |
| SSID | ssj0015792 |
| Score | 2.5307367 |
| SecondaryResourceType | review_article |
| Snippet | The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three... |
| SourceID | doaj liege proquest pubmed crossref karger |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2377 |
| SubjectTerms | Amino acids Antiviral Antiviral drugs Bacterial infections Cytokines Dendritic cells Gene expression Hepatitis HIV Human immunodeficiency virus Immunodeficiency virus Infections Influenza Influenza Virus Interferon Life sciences Microbiologie Microbiology Pandemics Phosphorylation Proteins Review Sciences du vivant Type I IFN classes Viral infection Viral infections Viruses |
| SummonAdditionalLinks | – databaseName: Karger Open Access dbid: M-- link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9QwEB1BEdALglIgUJBBHDhgkdix43BbClWLVE4U9WbZjo0qVtlqu4vEv2f8kYhK9LbanUyinXHmPU_yBuBtYwYTnGooFj9PW2tqapzhtOe-FhYBUhfi28in3-TxWfv1XJyX_Y74Lsyv-PxzkkadtQWw4H5ISFaovrsNd5BH8aiSf0rp3C8QXZ_7mo2gCml00RC6dugu3ONRvaRrm2tFKGn1YwHKp0aQuozt6psRZ6o8Rw_hQYGMZJFj_Ahu-XEP7uYhkn_24P7hNLPtMehIK8kJSft8wa8xpT6Sz3EZj25D8iExKmTh0tQIpMnEjAMpKk1k8U87myCcJT8u1mh9Up7YGvfh7OjL98NjWkYoUIfQaEMHbgWXzofW8rp3CPfquHXJjWm6wD3rVRt8RDHSG2V8x4wdrJEysFr2sUP7BHbG1eifAUFo4PGWpExUmHPBWiu5F8oLJofGGFfBu-k_1a7oi8cxF0udeIbo9RyJCt7MppdZVON_Rp9iYGaDqIOdvlitf-qyrDSzTFnXmcb0ouU8INwV3EdONCATcuhkP4d1djM5f5-ijM7shf7Nkvf0ebtE705b9M2k0qxVXIkKDqZk0GWNX2kkb0h2G67aCl7PP2PAY8vFjH61RZvUiFTIqyt4mpNovpIpGZ_fcI0vYBfRmcr7PQews1lv_UtEQBv7KiX_X4fy-z8 priority: 102 providerName: Karger AG – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3BbtQwELWgFYILglIgtCCDOHDAamLHjtML2haqFglOFO3Nsh27qlhly3YXib9nxnHSHoBbtJkdrTxjz5sZ7xtC3la2s9HrikHwC6x2tmTWW8FaEUrpACA1Ef-N_OWrOj2vP8_lPBfcrvO1yvFMTAd1t_RYIz8AqAypRSV0_eHqJ8OpUdhdzSM07pJtpC7DK13NfEq4Ktm0Q7ezkkxDcp2ZhSCCHyRoLDVyPd2KR4m2H2LRD7yFDUFpe4Gd63-DzxSETh6Rhxk90tlg7sfkTuh3yL1hnuTvHXL_eBzf9oQYzDDpGU0lvxhW4F2H9CPu6N6v6fAVNBCd-TRAAjJmavuOZsImOrvV2aaAbOn3yxVIn-XLW_0uOT_59O34lOVpCswDSlqzTjgplA-xdqJsPSC_EquYwtqqiSLwVtcxIKBRwWobGm5d56xSkZeqxWbtU7LVL_vwnFBACQFOJ22RbM5H55wSQeogueoqa31B3o1ranymGseJFwuTUg7Zmmn5C_JmEr0a-DX-JnSEhpkEkBI7fbBcXZi8wwx3XDvf2Mq2shYiAvKVImB61EFS5EHJ7mDWSc2o_H2yMihzl-YXT9rT82YB2r1xoJsrbXithZYF2R-dweTtfm1unLMgr6fXYHDsvtg-LDcgk3qSGlLsgjwbnGj6JQJZdQDbvfi_8j3yAPCaHipA-2RrvdqEl4CJ1u5Vcvw_g8wGmg priority: 102 providerName: ProQuest |
| Title | Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection |
| URI | https://karger.com/doi/10.1159/000495897 https://www.ncbi.nlm.nih.gov/pubmed/30537741 https://www.proquest.com/docview/2301911384 https://www.proquest.com/docview/2155168210 http://orbi.ulg.ac.be/handle/2268/248385 https://doaj.org/article/2b28bc7a1a95433f99953e6130d675c7 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB1BKwQXBKWUQFkZxIEDVpM4dhxu29KqRWqFEEV7s2zHlipWKVp2kfj3jD8S7QHEhUu0ys6OHM94543HeQPwptK99lZWFIOfo43RJdVWM9oxV3KDAKn14W3kyytxft18XPDFVquvcCYs0QOniTuqTS2NbXWlO94w5hHQcOYC6u0R69r4HjnGvDGZyvUD3napzllxKjGtzpxCGLuPIijmMrA8bUWiSNiPUehbOH-N4Wh3GWrWf4edMfycPYKHGTeSeRrvY7jjhj24lzpJ_tqD-ydj47YnoEJuSS5I3OzzboV-9Z58CGt5sGuSfhJMQ-Y2to7AXJnooSeZqonMt2raBDEt-XqzQumLfGxr2Ifrs9MvJ-c091GgFvHRmvbMcCas841hZWcR85Vh_5JpXbWeubqTjXcByginpXZtrU1vtBC-LkUXyrRPYWe4HdwzIIgPHP4vSR1o5qw3xgjmuHS8Fn2ltS3g7TinymaS8dDrYqlissE7NU1_Aa8n0e-JWeNPQsfBMJNAIMOON9BFVHYR9S8XKWA_mXVSMyp_F62MysyN-llH7fHzZonarTKouxZS1Y1kkhdwODqDygv9h8IMDjPeismmgFfT12jwUHfRg7vdoEysRkpMrgs4SE40jYQFPh1Edc__x4O-gAeI52TaITqEnfVq414iZlqbGdxtF-0Mdo9Prz59nsXFgtdLSn8DsmIRgg |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VRKhcEJQCKQUMAokDq2bt9caLhFD6UkLbCKEW9WZsrxdVjTYlTUD9U_xGZrwPegBuvUXJ7CjyjGe-z-OdAXgVm9wUTsURJj8fJdb0I-OMiDLh-9IiQBoU9Dby0SQdnSQfT-XpCvxq3oWha5VNTAyBOp85OiPfQqiM1CIWKvlw8T2iqVFUXW1GaFRuceCvfiJlu3w_3kX7vuZ8f-94ZxTVUwUih2hhEeXCSpE6XyRW9DOHCKhPp3nCmHhQCM8zlRSeEnvqjTJ-wI3NrUnTgvfTjIqWqPcWdBOBVKYD3e29yafPbd1CDrKqvhrLSCGdr3sZIWbYCmBcKuoudS0DhkEBmP3O6d43psHulGrl_4a7Ie3t34O7NV5lw8rB7sOKL9fgdjXB8moNVneagXEPQBOnZWMWDhkLP0d_fsd2KYaUbsGqR8gl2NCFkRXI0Zkpc1a3iGLDa7V0hliafTmbo_S4vi5WrsPJjaz0Q-iUs9I_Boa4xGM8VIba27nCWpsKL5WXPM1jY1wP3jRrql3d3JxmbEx1IDky0-3y9-BlK3pRdfT4m9A2GaYVoCbc4YvZ_Juu97TmlivrBiY2mUyEKBBrS-GJkOVIwxwqWa_M2qpplL8NVkZl9kz_4EF7-LyconanLermqdI8UULJHmw2zqDrAHOp_2yHHrxof0aDU73HlH62RJlQBVVI6nvwqHKi9p8I6uODaHLj_8qfw-ro-OhQH44nB0_gDqJFVZ0_bUJnMV_6p4jIFvZZvQ0YfL3pnfcb2VxEJw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VVjwuCEqBQAGDQOLAKrv2eteLhFBoiBoKFQeKcjO214sqok1JE1D_Gr-OGe-DHoBbb1EyO4o8M57v83hnAJ4mpjSVU0mEyc9HqTVxZJwRUSF8LC0CpLyit5E_HGb7R-m7mZxtwK_uXRi6VtntiWGjLheOzsiHCJWRWiRCpcOqvRbxcTx5ffI9oglSVGntxmk0LnLgz34ifTt9NR2jrZ9xPnn7aW8_aicMRA6RwyoqhZUic75KrYgLh2goppM9YUySV8LzQqWVpySfeaOMz7mxpTVZVvE4K6iAiXovwVYuZEIxls96spfIvGgqrYmMFBL7tqsRoodhgOVSUZ-pc7kwjAzAPPiNboBjQtyaU9X838A3JMDJDbjeIlc2alztJmz4ehsuN7Msz7bh6l43Ou4WaGK3bMrCcWPll-jZL9mYdpParVjzCDkHG7kwvALZOjN1ydpmUWx0rqrOEFWzz8dLlJ62F8fqHTi6kHW-DZv1ovZ3gSFC8bgzKkON7lxlrc2El8pLnpWJMW4Az7s11a5tc07TNuY60B1Z6H75B_CkFz1penv8TegNGaYXoHbc4YvF8qtuo1tzy5V1uUlMIVMhKkTdUniiZiUSModKdhqz9mo65S-ClVGZPdY_eNAePq_nqN1pi7p5pjRPlVByALudM-h2qznVfwJjAI_7n9HgVPkxtV-sUSbUQxXS-wHcaZyo_yeCOvogrrz3f-WP4ArGm34_PTy4D9cQNqrmIGoXNlfLtX-A0GxlH4YYYPDlooPuN5d4Rvc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Type+I+Interferons%3A+Distinct+Biological+Activities+and+Current+Applications+for+Viral+Infection&rft.jtitle=Cellular+physiology+and+biochemistry&rft.au=Li%2C+Shi-Fang&rft.au=Gong%2C+Mei-Jiao&rft.au=Zhao%2C+Fu-Rong&rft.au=Shao%2C+Jun-Jun&rft.date=2018-01-01&rft.issn=1421-9778&rft.eissn=1421-9778&rft.volume=51&rft.issue=5&rft.spage=2377&rft_id=info:doi/10.1159%2F000495897&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1015-8987&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1015-8987&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1015-8987&client=summon |